Titan Pharmaceuticals (NASDAQ:TTNP) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPGet Rating) in a note issued to investors on Thursday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

TTNP stock opened at $0.71 on Thursday. The stock’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $1.15. Titan Pharmaceuticals has a fifty-two week low of $0.66 and a fifty-two week high of $3.10.

A hedge fund recently raised its stake in Titan Pharmaceuticals stock. Morgan Stanley grew its stake in shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNPGet Rating) by 1,058,500.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 158,790 shares of the specialty pharmaceutical company’s stock after purchasing an additional 158,775 shares during the period. Morgan Stanley owned about 1.61% of Titan Pharmaceuticals worth $413,000 as of its most recent filing with the SEC. 18.86% of the stock is currently owned by institutional investors and hedge funds.

About Titan Pharmaceuticals (Get Rating)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union.

See Also

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.